Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinomas obtained from patients treated with trastuzumab...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Triulzi, Tiziana, De Cecco, Loris, Sandri, Marco, Prat, Aleix, Giussani, Marta, Paolini, Biagio, Carcangiu, Marialuisa L., Canevari, Silvana, Bottini, Alberto, Balsari, Andrea, Menard, Sylvie, Generali, Daniele, Campiglio, Manuela, Di Cosimo, Serena, Tagliabue, Elda
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695052/
https://ncbi.nlm.nih.gov/pubmed/26334217
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы